Innolife Pharma Inc. acquires rights to breakthrough in non-narcotic chronic pain treatment
Today, one in five Americans suffer with chronic pain (~ 60 millionadults) spending approximately $120 Billion a year and the aging baby boomershave reported in surveys more aches and pains than any previous generation.
New Medical Finding with Brain Scans and Functional MRI's
Modern Brain Imaging has revealed that most chronic pain is the result ofthe brain's inability to turn off pain messages from the body. In chronic painthe brain simply is not producing and releasing enough natural pain killers(such as endorphins) to stop the person's suffering. These new medicalfindings show that chronic pain sufferers from headaches, migraines,fibromyalgia, back pain, sciatica, arthritis or a combination of all of them,are caused by a low level of Natural Pain Killer's (such as Endorphins andothers) in the brain, as compared to people without chronic pain.
Over three years of in-clinic testing showed that this breakthroughall-natural program relieved significant chronic pain in 8 out of 10 peopleand with sustainable results. This non-narcotic, combination treatment hasbeen receiving accolades from chronic pain sufferers with major improvement inmood and energy and dramatic decreases in pain levels, allowing a return tonormal life function.
Innolife Pharma Inc. has an aggressive growth plan in place with aprojected target of 95 licensed clinics in 3 years with projected top lineannual revenue in excess of $30 million and a projected bottom line profit ofover $12 million annually (40+%).
With the aging demographic, chronic pain is becoming a larger and largerinternational epidemic. Innolife Pharma Inc. is positioned to be the leadingservice provider in this segment - with a business model that is designed toprovide excellent operating margins and tremendous growth for many years tocome.
About Innolife Pharma Inc.
Innolife Pharma Inc. (PINKSHEETS: INNP) is a small publicly tradedspecialty multi-discipline medical group focusing on licensing the NaturalPain Relief Center all-natural proprietary breakthrough in the treatment ofchronic pain.
This release contains forward-looking statements within the meaning andpursuant to the Safe Harbor provisions of the Securities Litigation Reform Actof 1995 and involve risks and uncertainties that may individually or mutuallyimpact the matters herein described, including but not limited to productdevelopment and acceptance, manufacturing, competition, regulatory and/orother factors, which are outside the control of the Company.
SOURCE Innolife Pharma Inc.
You May Also Like